Thirty-seven states (as of February 2, 2022) and the District of Columbia have approved comprehensive, publicly available medical marijuana/cannabis programs, while 11 states allow the use of “low THC, high cannabidiol (CBD)” products for medical reasons in limited situations or as a legal defense. On February 22, 2022, the Kansas Health Institute (KHI) hosted a virtual discussion about policy issues related to medical marijuana and compared laws in other states with provisions in two Kansas bills. Tatiana Y. Lin, M.A., and Linda J. Sheppard, J.D., led the discussion.
KHI materials related to this topic are linked below:
External resources referenced in the discussion include:
-
- National Conference of State Legislatures: Status of State Marijuana Legalization Decisions (February 2022)
To view specific topics from the agenda, move the slider to the time listed.
-
-
- Introduction: (0:00 on the recording)
- What is Marijuana? (4:11 on the recording)
- Efficacy and Public Health Impacts (5:14 on the recording)
- Poll: For which of the following conditions does substantial evidence exist to support medical marijuana efficacy? (5:43 on the recording)
- Health Risks (8:27 on the recording)
- Potential Public Health Impacts (8:50 on the recording)
- Medical Marijuana Laws Across the Country (14:00 on the recording)
- Racial Equity: States are Focused on These Issues (21:46 on the recording)
- Discussion: (24:22 on the recording)
- Kansas Medical Marijuana Bills (25:09 on the recording)
- Discussion (34:34 on the recording)
-